Roche Stands Firm On Mergers, Says Now Is Not The Time To Bulk Up
This article was originally published in The Pink Sheet Daily
Executive SummaryRoche’s next wave of primary care products will not reach the market before 2007. It would be "stupid" to merge now and wait for the products, company says.
You may also be interested in...
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
The innovator biopharma industry understandably concerned about a Trump Administration proposal to allow states to implement restrictive formularies while still collecting mandatory rebates. But the formulary protections in the Trump plan are an important message about the likely shape of any future changes to the US market.